Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
We examined plasma biomarker changes in cognitively normal individuals over 15.8 years.Apolipoprotein E (<i>APOE</i>) ε4 was related to lower amyloid beta (Aβ)<sub>42</sub>/Aβ<sub>40</sub> and greater increases in phosphorylated tau (p-tau)<sub>181</sub> and glial fibrillary acidic protein (GFAP).In <i>APOE</i> ε4 non-carriers, higher Alzheimer's disease (AD) polygenic risk score was related to greater Aβ<sub>42</sub>/Aβ<sub>40</sub> declines.P-tau<sub>181</sub>, NfL, and GFAP increases were greater among those who progressed to mild cognitive impairment.Results highlight the predictive value of plasma biomarkers during preclinical AD.
Authors
- Anja Soldan (ORCID: https://orcid.org/0000-0002-6193-0418)
- Timothy J. Hohman (ORCID: https://orcid.org/0000-0002-3377-7014)
- Jiangxia Wang (ORCID: https://orcid.org/0000-0002-1715-3981)
- Logan C. Dumitrescu (ORCID: https://orcid.org/0000-0002-9782-9944)
- Corinne Pettigrew
- Abhay Moghekar (ORCID: https://orcid.org/0000-0001-9464-1551)
- Kaj Blennow
- Tobias Bittner (ORCID: https://orcid.org/0000-0001-9256-0360)
- Marilyn Albert
Institutions
- Roche (Switzerland) (CH)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sahlgrenska University Hospital (SE)
- Sorbonne Université (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut du Cerveau (FR)
- University of Gothenburg (SE)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/dad2.70081
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Institutes of Health